Author
Listed:
- Daniel Becker
(Institute of Pharmacy, Medicinal Chemistry, Freie Universität Berlin)
- Zuzanna Kaczmarska
(Institute for Research in Biomedicine, Parc Científic de Barcelona
Institut de Biologia Molecular de Barcelona (CSIC), Parc Científic de Barcelona)
- Christoph Arkona
(Institute of Pharmacy, Medicinal Chemistry, Freie Universität Berlin)
- Robert Schulz
(Institute of Pharmacy, Medicinal Chemistry, Freie Universität Berlin)
- Carolin Tauber
(Institute of Pharmacy, Medicinal Chemistry, Freie Universität Berlin)
- Gerhard Wolber
(Institute of Pharmacy, Medicinal Chemistry, Freie Universität Berlin)
- Rolf Hilgenfeld
(Institute of Biochemistry, University of Lübeck
German Center for Infection Research (DZIF), Hamburg–Lübeck–Borstel Site, University of Lübeck)
- Miquel Coll
(Institute for Research in Biomedicine, Parc Científic de Barcelona
Institut de Biologia Molecular de Barcelona (CSIC), Parc Científic de Barcelona)
- Jörg Rademann
(Institute of Pharmacy, Medicinal Chemistry, Freie Universität Berlin)
Abstract
Small-molecule fragments binding to biomacromolecules can be starting points for the development of drugs, but are often difficult to detect due to low affinities. Here we present a strategy that identifies protein-binding fragments through their potential to induce the target-guided formation of covalently bound, irreversible enzyme inhibitors. A protein-binding nucleophile reacts reversibly with a bis-electrophilic warhead, thereby positioning the second electrophile in close proximity of the active site of a viral protease, resulting in the covalent de-activation of the enzyme. The concept is implemented for Coxsackie virus B3 3C protease, a pharmacological target against enteroviral infections. Using an aldehyde-epoxide as bis-electrophile, active fragment combinations are validated through measuring the protein inactivation rate and by detecting covalent protein modification in mass spectrometry. The structure of one enzyme–inhibitor complex is determined by X-ray crystallography. The presented warhead activation assay provides potent non-peptidic, broad-spectrum inhibitors of enteroviral proteases.
Suggested Citation
Daniel Becker & Zuzanna Kaczmarska & Christoph Arkona & Robert Schulz & Carolin Tauber & Gerhard Wolber & Rolf Hilgenfeld & Miquel Coll & Jörg Rademann, 2016.
"Irreversible inhibitors of the 3C protease of Coxsackie virus through templated assembly of protein-binding fragments,"
Nature Communications, Nature, vol. 7(1), pages 1-9, November.
Handle:
RePEc:nat:natcom:v:7:y:2016:i:1:d:10.1038_ncomms12761
DOI: 10.1038/ncomms12761
Download full text from publisher
Corrections
All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:nat:natcom:v:7:y:2016:i:1:d:10.1038_ncomms12761. See general information about how to correct material in RePEc.
If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.
We have no bibliographic references for this item. You can help adding them by using this form .
If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.
For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Sonal Shukla or Springer Nature Abstracting and Indexing (email available below). General contact details of provider: http://www.nature.com .
Please note that corrections may take a couple of weeks to filter through
the various RePEc services.